

1 **Heterogeneity of *Staphylococcus epidermidis* in prosthetic joint infections: Time to**  
2 **reevaluate microbiological criteria?**

3

4 Micael Widerström,<sup>a</sup># Marc Stegger,<sup>b</sup> Anders Johansson,<sup>a</sup> Bharat Kumar Gurram,<sup>a</sup> Anders  
5 Rhod Larsen,<sup>b</sup> Lars Wallinder,<sup>c</sup> Helen Edebro,<sup>a</sup> Tor Monsen<sup>a</sup>

6 <sup>a</sup>Department of Clinical Microbiology, Umeå University, Umeå, Sweden

7 <sup>b</sup>Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark

8 <sup>c</sup>Department of Orthopedics, University Hospital of Umeå, Umeå, Sweden

9

10 Running title: Within-host genetic diversity of *S. epidermidis* in PJI

11

12 # Corresponding author: Micael Widerström, [micael.widerstrom@umu.se](mailto:micael.widerstrom@umu.se)

13

14

15

16

17

18

19

20

21 **Keywords**

22 Molecular epidemiology, genomics, *Staphylococcus epidermidis*, multidrug-resistant,  
23 transmission, prosthetic joint infection, within-patient variation, diagnosis

24

25 **ABSTRACT**

26 Prosthetic joint infection (PJI) is a feared complication after arthroplasty with *Staphylococcus*  
27 *epidermidis* as a major pathogen. One diagnostic criteria for PJI diagnosis is the finding of  
28 phenotypically identical organisms based on common laboratory tests in two or more  
29 periprosthetic microbial cultures. Because of phenotypical variation within a genetic clone,  
30 and clonal variation within a phenotype, the criteria may be ambiguous. Here, we investigate  
31 the extent of diversity among coagulase-negative staphylococci in PJI and characterize in  
32 detail *S. epidermidis* isolates from these infections.

33 We performed a retrospective cohort study of 62 consecutive patients with PJI caused by  
34 coagulase-negative staphylococci (CoNS) from two hospitals in Northern Sweden. From 16  
35 of the patients, two to nine *S. epidermidis* isolates were available for whole-genome analyses.  
36 Hospital-adapted multidrug-resistant genetic clones of *S. epidermidis* were identified in 40/62  
37 (65%) of the PJIs using a combination of analysis by pulsed-field gel electrophoresis and  
38 multiple-locus sequence typing. Whole genome sequencing showed presence of multiple  
39 sequence types (STs) in seven (7/16, 44%) PJIs. Among isolates of the same ST, within-  
40 patient phenotypical variation in antibiotic susceptibility and/or whole-genome antibiotic  
41 resistance gene content was frequent (11/16, 69%).

42 These results highlight the ambiguity of using phenotypical characterization of *S. epidermidis*  
43 as diagnostic criteria in PJI. The results call for larger systematic studies to determine the  
44 frequency of CoNS diversity in PJIs, the implications of such diversity for microbiological  
45 diagnostics, and for the therapeutic outcome in patients.

46

47

48

49

## 50 INTRODUCTION

51 Prosthetic joint replacement is one of the most important medical innovations of the  
52 20th century, and it has improved the quality of life for millions of people worldwide by  
53 providing pain relief, restoring joint function, mobility and independence (1, 2). In contrast,  
54 prosthetic joint infections (PJIs) after joint replacements are devastating complications  
55 bringing high hospital costs and increased in-hospital mortality (3). The diagnosis of a PJI  
56 and its treatment are both challenging (4). The post-operative infections that normally occur  
57 within two years of surgery are not neglectable with an infection rate after hip or knee  
58 replacement of between 1-2% (2, 4-9). Register datasets from European countries indicate a  
59 significant increase in early revisions for manifest or suspected infection during the last  
60 decades (9, 10), likely caused by an aging population and higher levels of obesity in general.  
61 These European national quality registers lack data on microbiological etiology, but several  
62 investigations have documented that *Staphylococcus aureus* and coagulase-negative  
63 staphylococci (CoNS), and in particular *Staphylococcus epidermidis*, accounts for the  
64 majority of PJIs (11, 12).

65 Previous molecular epidemiological studies have revealed clonal spread of hospital-  
66 adapted multidrug-resistant *S. epidermidis* (HA-MDRSE) between ward units, hospitals and  
67 even countries (13-19). Recently, global spread of HA-MDRSE have been confirmed using  
68 whole-genome sequencing (WGS) (20-22), that also highlighted the distinct selection of  
69 resistance as indicative of adaption to the hospital environment and the compounds used in  
70 the prevention of PJI (23). However, the ramification of the dissemination of HA-MDRSE  
71 lineages linked to the increasing incidence of PJI is limited (23-26). This lack of data has  
72 historically, in part, been due to the demanding assessment of CoNS in clinical cultures since  
73 CoNS constitutes a ubiquitous part of the human skin microbiota, which infers difficulties in  
74 distinguishing between isolates from contamination and true infection (27). The current

75 international clinical guidelines for defining a PJI diagnosis reflect this inability since the  
76 finding of two positive periprosthetic cultures with phenotypically “identical” or  
77 “indistinguishable” organisms is included in the diagnostic set of criteria, with the phenotype  
78 being based on common laboratory tests for genus and species identification and antibiograms  
79 (28-30). Since phenotypic morphological variation (31), including small colony variants  
80 (SCVs) and different antibiogram has been reported in monoclonal CoNS infections (32-34),  
81 the term “phenotypically identical organisms” is ambiguous. Here, we investigate the extent  
82 of diversity among coagulase-negative staphylococci in PJI and in detail characterize *S.*  
83 *epidermidis* in these infections.

## 84 **MATERIALS AND METHODS**

### 85 **Study population**

86 The study population was recruited from two hospitals in Northern Sweden, Umeå University  
87 Hospital (UH), and Östersund County hospital (ÖH), which annually perform approximate  
88 260 and 470 primary hip or knee arthroplasties, respectively, with a reported <2-year  
89 infection rate for primary hip arthroplasties of 1.7-2.9% respectively, according to data from  
90 the Swedish Arthroplasty Registers (35, 36)

91 All patients were identified using the laboratory information systems and the presence of  
92 CoNS in  $\geq 2$  periprosthetic tissue biopsies retrieved from revision surgery in clinically  
93 suspected patients with PJI between December 2008 and June 2011. The used clinical workup  
94 was to obtain five tissue specimens from different sites of the periprosthetic tissue using new  
95 set of sterile instruments for separate specimens, each of which were divided in two: one half  
96 was placed in sterile container for direct culturing on blood agar, McLeod agar and anaerobic  
97 blood agar and incubated at 37°C for 2 days. The other half was placed in thioglycolate broth  
98 and cultured at 37°C for 7 days under anaerobic conditions. Visually negative broths were  
99 terminally subcultured on blood agar, McLeod agar and anaerobic agar and incubated for a

100 further 2 days. Diagnosis was based on Infectious Disease Society of America (IDSA,  
101 [www.idsociety.org](http://www.idsociety.org)) PJI diagnostic criteria ‘identical microorganisms isolated from two or  
102 more cultures’ (29) and classified according to when they occurred after implantation: acute,  
103 within 1–3 months; delayed, 3 months to 1 year; late, more than 1 years (28). Medical records  
104 were reviewed for additional data: Concomitant diseases, previous hospitalization during the  
105 last year, intraoperative clinical finding by the surgeon, surgical treatment of the PJI, and  
106 outcome at 2-year follow-up.

### 107 **Bacterial strains**

108 CoNS cultured from  $\geq 2$  perioperative tissue specimens from revision surgery of clinically  
109 suspected PJI patients were consecutively collected. Based on difference in morphology, one  
110 to two isolates resembling CoNS were picked from each tissue culture for further  
111 investigations. The bacterial isolates were stored at  $-70^{\circ}\text{C}$  in preservation media (Trypticase  
112 Soy Broth, BD Diagnostic Systems, Sparks, MD, USA) until further examination. In total,  
113 131 CoNS isolates from 62 PJIs patients were included for antimicrobial susceptibility testing  
114 and pulsed-field gel electrophoresis (PFGE). Only one isolate was available for analysis with  
115 PFGE in 40 of the 62 PJIs; 34 *S. epidermidis* PJIs and six non-*S. epidermidis* CoNS PJIs  
116 infections (Fig. S1 + Fig. S2). Of the remaining 22 PJIs, 16 included multiple *S. epidermidis*  
117 isolates that were available for WGS (Fig. S1). PJIs that had more than one *S. epidermidis*  
118 isolate saved were selected for WGS including all available *S. epidermidis* isolates in each  
119 patient.

### 120 **Identification**

121 CoNS isolates were identified to species level using matrix–assisted laser  
122 desorption/ionization time–of–flight mass spectrometry (MALDI-TOF MS), using a Microflex  
123 LT (Bruker Daltonik GmbH, Bremen, Germany) and MALDI Biotyper software v3.1

124 DB7311 (Bruker Daltonik), according to the manufacturer's instructions. A score >2.0 was  
125 required for species identification (37).

### 126 **Antibiotic susceptibility testing**

127 Antimicrobial susceptibility testing by disc diffusion was performed according to the  
128 recommendations of the European Committee on Antimicrobial Susceptibility Testing  
129 (EUCAST, <http://www.eucast.org>). Briefly, staphylococci were suspended in saline to  
130 McFarland 0.5 and inoculated on Mueller-Hinton II Agar (Becton Dickinson, Cockeysville,  
131 MD, USA) before application of the antimicrobial discs. Oxacillin resistance was screened  
132 using 10 µg cefoxitin disc on Mueller Hinton II Agar supplemented with 2% NaCl.  
133 Constitutive and inducible resistance to clindamycin was determined with the D-shaped disc  
134 diffusion method (Oxoid AB, Sweden). Agar plates were incubated at 35°C for 20h before  
135 evaluation. The clinical breakpoints were according to EUCAST recommendation (v10.0).  
136 Heteroresistance testing for vancomycin was not performed. Multidrug-resistance (MDR) was  
137 defined as resistance towards  $\geq 3$  antimicrobial classes.

### 138 **PFGE and multilocus sequence typing (MLST)**

139 PFGE and MLST were performed as previously described (38). Sequence types (STs) were  
140 assigned using the *S. epidermidis* MLST database (<https://pubmlst.org/sepidermidis/>). PFGE  
141 was performed on all isolates ( $n=131$ ). *S. epidermidis* PFGE types that included at least three  
142 isolates was further analyzed using MLST.

### 143 **Genome sequencing and analyses**

144 Whole-genome sequencing was performed on all 69 *S. epidermidis* isolates available from the  
145 16 PJI patients using Illumina MiSeq and the 300-cycle MiSeq Reagent Kit v3 to generate  
146 paired-end 150-bp reads using manufacturer's instructions with purified DNA using the  
147 Qiagen Blood and Tissue kit (Fig S1, Table S1). The generated sequencing data were  
148 subjected to quality control using bifrost (<https://github.com/ssi-dk/bifrost>) to ensure adequate

149 sequencing quality of all isolates. The sequence data was assembled using SPAdes v3.9.0  
150 (39). Raw reads were aligned against the *S. epidermidis* ATCC 12228 reference chromosome  
151 (GenBank accession ID CP0222479) for detection of single nucleotide polymorphisms  
152 (SNPs) using NASP v1.0.0 (40) after duplicated regions in the reference were removed using  
153 NUCmer. NASP was also used to detect intraspecies contamination. All positions with <10-  
154 fold coverage or if the variant was present in <90% of the base calls were excluded using  
155 GATK (41). The identified SNPs in the core genome was used to infer phylogenetic  
156 relationships using PhyML v3 (42) with Smart Model Selection (43).  
157 Resistance mechanisms were detected as previously described (23). Briefly, acquired  
158 antimicrobial resistance genes were detected using the curated database used by ResFinder  
159 v3.1 (44) to search for gene matches using ABRicate v0.7 ([https://github.](https://github.com/tseemann/abricate)  
160 [com/tseemann/abricate](https://github.com/tseemann/abricate)) on the assembled genomes using a >80% hit length and >90%  
161 sequence identity criteria.

#### 162 **Data availability**

163 The whole-genome sequence data generated in this study have been submitted to the  
164 European Nucleotide Archive under BioProject ID PRJEB44086.

165

#### 166 **Statistics**

167 All statistical analyses were performed using the SPSS v24 (SPSS Inc., Chicago, IL, USA)  
168 software package. Fisher's exact test was used to test for association in all two-way tables. A  
169 value of  $p < 0.05$  was considered significant.

170 **Research ethics.** The study was approved by the Research Ethics Committee (No 2012–477–  
171 31M) of the Faculty of Medicine, Umeå University, Sweden.

172

#### 173 **RESULTS**

174 **Clinical characteristics**

175 From December 2008 to June 2011, 62 consecutive patients (34 men and 28 women; median  
176 age 68.6 years) with revision or resection arthroplasties due to CoNS-related PJI were  
177 identified (Table 1). Thirty-five of 62 (56%) patients were included at UH and 27/62 (44%) at  
178 ÖH. The vast majority of patients were diagnosed with hip or knee PJI (59/62, 95%) (Table  
179 1). The distributions were similar between hip or knee revision or centers regarding gender,  
180 age, and reasons for primary arthroplasty (data not shown). Early revision or resection  
181 surgeries (<3 months after prosthesis implantation) and two-stage exchanges were performed  
182 in the majority of patients while debridement, antibiotics and implant retention (DAIR)  
183 surgery was used in ~1/3 (21/62; 34%) of patients. At two-year follow-up, 15/62 (24%)  
184 patients had undergone resection, required further surgeries or suppressive antimicrobial  
185 treatment and were assessed as failures.

186 **Microbiological findings and genetic analyses by PFGE and MLST**

187 In total, 131 CoNS isolates were available from the 62 patients of PJIs with *S. epidermidis*  
188 ( $n=107$ ; 85%), *Staphylococcus capitis* ( $n=11$ ; 8%) and *Staphylococcus hominis* ( $n=8$ ; 4%) as  
189 the most frequent species as determined by MALDI-TOF MS (Table 2, Fig. S1). PFGE  
190 analysis of all 131 isolates revealed overall genetic clustering by species and subsequent  
191 MLST on selected *S. epidermidis* PFGE types revealed two major clusters corresponding to  
192 ST215 ( $n=32$ ) and ST2 ( $n=41$ ) (Fig. S2). In addition, two single locus variants (SLVs) of  
193 ST215 (ST434) and ST2 (ST188) were identified, the major cluster including SLVs further  
194 denoted as the ST215 and ST2 lineages, respectively (Fig. 1). There were 11 patients with  
195 genetically indistinguishable isolates using PFGE and MLST (PFGE type A1/ST215), and  
196 another seven patients with genetically indistinguishable isolates belonging to PFGE type  
197 C/ST2 (Fig. S2). Isolates of the two major lineages ST2 or ST215 were found in 40/52 (77%)



198 of the *S. epidermidis* PJI patients and were equally common among hip and knee PJIs and  
199 present throughout the study period at both hospitals (Fig. 1).  
200 Among *S. epidermidis* isolates, the levels of antimicrobial resistance were as follows:  
201 cefoxitin (80%), gentamicin (90%), norfloxacin (79%), trimethoprim-sulfamethoxazole  
202 (75%), clindamycin (63%), fusidic acid (42%), and rifampicin 33% (Table S2). No resistance  
203 to vancomycin and/or linezolid was detected. Significant differences in antimicrobial  
204 susceptibility were identified when comparing the two major genetic clusters (Table S2). All  
205 32 isolates of ST215 lineage exhibited fusidic acid resistance compared to 21% in ST2  
206 lineage ( $P<0.0001$ ). In contrast, rifampicin resistance was significantly more common among  
207 isolates in the ST2 lineage than in the ST215 lineage ( $P=0.0002$ ).

#### 208 **Phenotypic diversity of coagulase-negative staphylococci in PJI**

209 The majority (43/62; 69%) of the PJIs were monomicrobial with *S. epidermidis* identified in  
210 33/43 (77%) of PJI patients followed by *S. capitis* ( $n=5$ ) and *S. hominis* ( $n=2$ ) (Table 2). *S.*  
211 *epidermidis* was identified in all 19 polymicrobial PJIs, most frequently in combination with  
212 *Enterococcus faecalis* ( $n=7$ ), *Escherichia coli* ( $n=3$ ) or *S. hominis* ( $n=2$ ), and with similar  
213 frequencies in hip and knee revision arthroplasties with 11/37 (30%) and 6/20 (33%),  
214 respectively. There was no difference in the distribution of the two major lineages ST215 and  
215 ST2 among monomicrobial and polymicrobial PJIs (Table S3). The presence of sinus tract  
216 with communication to the joint in PJI patients was reported in only 2/19 (11%)  
217 polymicrobial *S. epidermidis* PJIs (*Peptostreptococcus* and *E. faecalis*, respectively). CoNS  
218 species, other than *S. epidermidis*, were more common in late PJIs ( $P=0.0004$ ) (data not  
219 shown). All ten monomicrobial non-*S. epidermidis* CoNS infections were considered cured at  
220 2-year follow-up compared to 24/33 (73%) monomicrobial *S. epidermidis* PJI and 13/19  
221 (68%) polymicrobial PJIs.

#### 222 **Whole-genome analyses of *S. epidermidis* in prosthetic joint infections**

223 In 16 of the 62 PJI patients, nine of which were monomicrobial, multiple *S. epidermidis*  
224 isolates ( $n=69$ ) in different samples from the same patient were available for WGS (Fig S1,  
225 Table 4). Between two to nine isolates per patient were available, and genomic analysis of  
226 these identified three major clusters: ST59/ST965 in two PJIs, ST215 lineage in five and ST2  
227 lineage in nine PJIs as illustrated in Fig. 1. Nine of the 16 (56%) patients were infected by a  
228 single *S. epidermidis* lineage while seven (44%) patients were infected by between two to five  
229 different *S. epidermidis* lineages (Fig. 3). Based on a conserved core genome of 73% (1.83  
230 Mb) across the entire collection of *S. epidermidis* PJI isolates, we found the within-patient  
231 genetic diversity among isolates from individual STs ranging from 10 to 107 SNPs, whereas  
232 PJI patients infected by multiple STs had 100 to 39,618 SNPs between isolates (Table S1).  
233 Analyses of between-patients diversities in the three major STs, revealed mean pairwise SNP  
234 distances of 61 for ST59, 58 for ST215, and 1,012 for ST2 (Fig. 2). As should be expected,  
235 the within-patient diversity was lower (4, 38 and 13 mean pairwise SNP distances for ST59,  
236 ST215 and ST2, respectively) for PJIs with multiple unique isolates of the same lineage. The  
237 largest pairwise isolate SNP difference in a patient infected by isolates of a single ST was 107  
238 SNPs (ST215 in patient 1, see Fig. S3). Notably, SNP distances between two isolates of an ST  
239 can be similar between-patients and within-patients (Fig. 2). The smallest SNP distance  
240 between two ST215 PJI isolates from different patients, that had undergone revision surgery  
241 at separate hospitals and two years apart, were 23 SNPs (isolates 238 and 196 from patient 1  
242 and 37, respectively, see Fig 1).

### 243 **Virulence and resistance determinants in *S. epidermidis* lineages**

244 There was a high degree of concordance between phenotypic antimicrobial resistance and  
245 antimicrobial resistance genes identified by WGS (Table S4). Our analyses showed that some  
246 antibiotic resistance genes were also associated with ST types: *fusB* acid and *tet(K)*,  
247 conferring resistance to fusidic acid and tetracycline respectively, were detected only in

248 ST215/ST434, ST188 and ST59. Likewise, mutations in *gyr(A)*, conferring resistance to  
249 fluoroquinolones, were detected in isolates belonging to ST2, ST22 and ST215, whereas *rpoB*  
250 mutations conferring rifampicin resistance were identified in both ST2 lineages and in  
251 sequence type 434, but not in any of the ST215 isolates (Fig. 1, Table S1).

### 252 **Within-patient variations in phenotype and genotypic resistance**

253 When we compared multiple *S. epidermidis* isolates collected from individual PJI patients,  
254 variation in antibiograms was identified in 13 of the 16 (81%) PJIs (Table 3). The differences  
255 in susceptibility ranged from between one to five antimicrobials (Figure 1, Table 4) with  
256 colony polymorphism between isolates observed in all patients (data not shown). Variation in  
257 antibiotic resistance gene content was also apparent comparing multiple isolates of the same  
258 sequence type in one patient (Fig 1, Tabl S1); in patient 1, seven ST215 isolates varied in  
259 genetic content regarding *mecA*, *tet(K)* and *ermC* and *folA* mutations.

### 260 **Temporal within-patient variations in phenotype and genotypic resistance**

261 *S. epidermidis* isolates from separate patients at different time points were available in four  
262 patients (28, 42, 43, 58) (Table S1). In patient 28, two ST2 isolates separated by 518 days,  
263 showed acquisition of phenotypic and genotypic gentamicin resistance (*qacA*, *aac(6')*-  
264 *aph(2'')*), phenotypic resistance to fusidic acid (not acquisition of *fusB* or detectable mutation  
265 in *fusA*) and reversion of *folA* F99Y mutation. In patient 43, five ST 2 isolates separated by  
266 308 days, had variability of *ermC* content and loss of *qacA*. In patient 58 having two ST 2 and  
267 one ST188 isolates, acquisition of *fusB*, *tet(K)*, rifampicin-mutation (S486Y), *folA*-F99Y  
268 mutation and loss of *ermC* during treatment with rifampicin and fusidic acid was observed. In  
269 patient 42, four ST188 isolates, separated by 162 days, showed variability in content of *emrC*  
270 and *tet(K)* and in phenotypic erythromycin/clindamycin resistance.

## 271 **DISCUSSION**

272 Here, we investigated the diversity among CoNS in PJI and in detail characterized the *S.*  
273 *epidermidis* isolates in these infections. We found that the within-patient diversity of *S.*  
274 *epidermidis* was considerable with variations in phenotypic and genotypic resistance in the  
275 majority (13/16; 81%) of patients, and importantly also when comparing isolates of the same  
276 sequence type. In addition, even when considering the inherent difficulty of ruling out the  
277 possibility that a single *S. epidermidis* isolate may represent a contamination, *S. epidermidis*  
278 isolates belonging to different sequence types were detected in several PJIs (7/16; 44%).  
279 These findings underscore the complexity in assessing whether *S. epidermidis* from multiple  
280 cultures in possible PJI cases meet the current criteria for microbiological diagnosis of PJI, i.e.  
281 a finding of phenotypically identical organisms in two positive periprosthetic cultures. Hence,  
282 with the present guidelines there is a risk that PJIs are incorrectly dismissed as contamination  
283 preventing proper microbial diagnosis and treatment.

284 Before this study, there was limited data on the within-patient genetic diversity of CoNS  
285 isolates in PJI (34, 45). Other polyclonal device-related infections have been described, and in  
286 addition diversification and evolution of *S. epidermidis* during infection within a patient (45-  
287 47). Here, we show that while only a single sequence type was detected in the majority (9/16)  
288 of the PJIs, polyclonality was detected in 44% (7/16) of all patients with between two to five  
289 different sequence types. Importantly, when at least three *S. epidermidis* isolates were  
290 characterized in each PJI, different sequence types were identified in 5/11 (45%) and a  
291 difference in antibiograms in almost all patients (10/11, 91%). Obviously, among PJI where  
292 only two *S. epidermidis* isolates were available for characterization, polyclonal infection was  
293 more rarely detected (2/5 patients, see Table 4). These results are consistent with a recent  
294 German study analyzing paired isolates from 55 orthopedic device-related infection cases  
295 with a timeframe between 6 to 428 days between isolates, with 6/55 (11%) being assessed as  
296 polyclonal (25). The result of the present study suggests that increasing the number of *S.*

297 *epidermidis* isolates for characterization, and preferably obtained from different tissue  
298 specimens is important to determine the diversity among the isolates and reduce the risk of  
299 incorrect dismissal as contaminants. Further, the inclusion of more than two isolates will  
300 improve the basis for making decisions on antibiotic therapy and for characterizing the  
301 clinical condition as a relapse or a reinfection.

302 We found a clear example of within-patient genetic variation of the ST2 *S. epidermidis*  
303 lineage in one of the patients (patient 58). This exemplifies that *S. epidermidis* can adapt to  
304 the selective pressures of long-term antimicrobial treatment by acquisition of resistance genes  
305 to overcome ongoing rifampicin and fusidic acid treatment. Since polyclonal *S. epidermidis*  
306 infections have mainly been reported for device-related infections other than PJI, and  
307 considering the reporting of within-patient evolution (45, 47), a more generous definition of  
308 “indistinguishable isolates” has been suggested allowing up to two differences in drug  
309 susceptibility profiles (48).

310 Confirming previous data, HA-MDRSE lineages were the cause of the majority of *S.*  
311 *epidermidis* PJI over a period of more than two years in the two hospitals in Northern Sweden  
312 (13, 14, 24, 38). The low pair-wise isolate diversity of the ST215 lineage found in two PJIs  
313 where isolates were collected more than one year apart in the same hospital (2 SNPs), or  
314 separate hospitals (23 SNPs) is supportive for that ST215 is persistent in the hospital setting.  
315 This is in contrast to *S. aureus* PJIs where data supports that there is limited hospital-adapted  
316 transmission of genetic lineages (49-51). The findings in this study fits with a previously  
317 described scenario of a global dissemination of multidrug-resistant lineages of *S. epidermidis*  
318 (14, 20, 52, 53). The scenario of hospital-adapted transmission was further corroborated by a  
319 recent large PJI study of *S. epidermidis* from Sweden (23). The adaptation of ST2 and ST215  
320 lineages to the hospital environment includes common genomic traits (*IS256*) and and high  
321 prevalence of antimicrobial resistance genes even though some lineage dependent differences

322 are evident (20, 23, 54). The primary source of HA-MDRSE lineages and the route of  
323 transmission is uncertain. In the subset of 26 PJI patients that had not been hospitalized during  
324 the last year, 12 patients were infected by ST215 or ST2 lineages and a majority of these PJI  
325 were classified as early infections, suggesting that a history of previous hospitalization is not a  
326 prerequisite for acquiring HA-MDRSE PJI. Recent data suggests that current perioperative  
327 prevention regimens for PJI selects for MDRSE either from the patients normal flora or by  
328 facilitating acquisition from the hospital environment (23).

329 Polymicrobial infections including *S. epidermidis* were common in the PJIs investigated  
330 here and in line with previous data, *E. faecalis* was the most frequent companion microbe  
331 (55). In most patients, both *S. epidermidis* and the companion microbe was found in the  
332 majority of tissue specimens in each patient, making contamination less likely, even if that  
333 possibility cannot be excluded.

334 The results presented here have practical implications. The finding of within-patient  
335 diversity of *S. epidermidis* suggests that the clinical microbiology assessment of a PJI needs to  
336 be evaluated (56). Based on our data, characterizing more than two isolates phenotypically  
337 and genotypically will improve assessment whether microbiological diagnostic criteria for PJI  
338 are met. More than two isolates will also provide more information for deciding on  
339 appropriate targeted antibiotic therapy and facilitate the evaluation whether a future infection  
340 episode is due to relapse or is a reinfection. The present clinical microbiology methodology  
341 for detection of genetic heterogeneity is laborious and expensive but recent advance may  
342 change that in the near future. New culture-independent methods that can be applied in  
343 clinical laboratories should facilitate rapid assessment of clonality and population structure of  
344 *S. epidermidis* communities in PJI (57). Another approach ready to use is culturing of  
345 multiple PJI specimens followed by sequencing of multiple microbial isolates as part of PJI  
346 routine microbial diagnostics. We think that given the high cost of PJIs, it is realistic to

347 implement routine PJI diagnostics using smaller scale rapid sequencing technology with a  
348 turn-around time including bioinformatics of 1-2 days (58)

349 Limitations of the study include a retrospective cohort design. Although prospective  
350 studies are generally preferred we believe that this is not crucial to investigate *S. epidermidis*  
351 populations causing PJIs, we note that an earlier study from central Sweden showed that the  
352 population structure of *S. epidermidis* remained fairly stable over the last 10 years (23).  
353 Perhaps more important, larger numbers of isolates per patient would have improved the  
354 study. Multiple *S. epidermidis* isolates were available for WGS analysis only in a minority of  
355 PJIs. With this limitation, the microbiological findings of heterogeneity still underline that the  
356 present-day guidelines for PJI diagnosis may be sub-optimal. Lastly and most importantly, it  
357 cannot be ruled out that some of the detected and characterized isolates constitute  
358 contaminants and are not truly invasive, however, all PJI patients were included consecutively  
359 and met IDSA's criteria for PJI. Further, we used new sets of knife blades for skin incision,  
360 subcutaneous incision and new sets of sterile instruments for separate tissue specimens to  
361 limit the risk of contamination.

362 In conclusion, the results outline that the within-patient genetic diversity in *S. epidermidis*  
363 isolates was substantial with variation in both antibiotic susceptibility and resistance gene  
364 content. The findings highlight the complexity and ambiguity of phenotypical assessment of  
365 CoNS isolates from periprosthetic tissue cultures as diagnostic criteria in PJI and calls for  
366 larger systematic studies to determine the implications for microbiological diagnosis and the  
367 clinical significance of these results for the therapeutic outcome in patients.

368

## 369 **SUPPLEMENTAL MATERIAL**

370 SUPPLEMENTAL FILE 1

371

372 **ACKNOWLEDGEMENTS**

373 Preliminary data from this study was presented at ISSSI 2014.

374 Source of Funding

375 The project was supported by the following: the Swedish Society of Medicine SLS-24993,  
376 SLS-413681; the Research and Development Unit, Jämtland County Council, Sweden; and  
377 through a regional agreement between Umeå University and Region Västerbotten. The  
378 funders had no role in study design, data collection and interpretation, or the decision to  
379 submit the work for publication.

380 **Conflict of Interest.**

381 The authors have none conflict of interest to declare



382 **References**

- 383 1. Learmonth ID, Young C, Rorabeck C. 2007. The operation of the century: total hip  
384 replacement. *Lancet* 370:1508-19.
- 385 2. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. 2007. Projections of primary and revision hip  
386 and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am* 89:780-  
387 5.
- 388 3. Shahi A, Tan TL, Chen AF, Maltenfort MG, Parvizi J. 2017. In-Hospital Mortality in  
389 Patients With Periprosthetic Joint Infection. *J Arthroplasty* 32:948-952 e1.
- 390 4. Del Pozo JL, Patel R. 2009. Clinical practice. Infection associated with prosthetic joints. *N*  
391 *Engl J Med* 361:787-94.
- 392 5. Tande AJ, Osmon DR, Greenwood-Quaintance KE, Mabry TM, Hanssen AD, Patel R.  
393 2014. Clinical characteristics and outcomes of prosthetic joint infection caused by small  
394 colony variant staphylococci. *MBio* 5:e01910-14.
- 395 6. Brochin RL, Phan K, Poeran J, Zubizarreta N, Galatz LM, Moucha CS. 2018. Trends in  
396 Periprosthetic Hip Infection and Associated Costs: A Population-Based Study Assessing the  
397 Impact of Hospital Factors Using National Data. *J Arthroplasty* 33:S233-S238.
- 398 7. Patel A, Pavlou G, Mujica-Mota RE, Toms AD. 2015. The epidemiology of revision total  
399 knee and hip arthroplasty in England and Wales: a comparative analysis with projections for  
400 the United States. A study using the National Joint Registry dataset. *Bone Joint J* 97-  
401 *B*:1076-81.
- 402 8. Lamagni T. 2014. Epidemiology and burden of prosthetic joint infections. *J Antimicrob*  
403 *Chemother* 69 Suppl 1:i5-10.
- 404 9. Lenguerrand E, Whitehouse MR, Beswick AD, Jones SA, Porter ML, Blom AW. 2017.  
405 Revision for prosthetic joint infection following hip arthroplasty: Evidence from the  
406 National Joint Registry. *Bone Joint Res* 6:391-398.

- 407 10. Dale H, Fenstad AM, Hallan G, Havelin LI, Furnes O, Overgaard S, Pedersen AB,  
408 Karrholm J, Garellick G, Pulkkinen P, Eskelinen A, Makela K, Engesaeter LB. 2012.  
409 Increasing risk of prosthetic joint infection after total hip arthroplasty. *Acta Orthop* 83:449-  
410 58.
- 411 11. Tande AJ, Patel R. 2014. Prosthetic joint infection. *Clin Microbiol Rev* 27:302-45.
- 412 12. Rosteius T, Jansen O, Fehmer T, Baecker H, Citak M, Schildhauer TA, Gessmann J. 2018.  
413 Evaluating the microbial pattern of periprosthetic joint infections of the hip and knee. *J Med*  
414 *Microbiol* 67:1608-1613.
- 415 13. Widerstrom M, Monsen T, Karlsson C, Wistrom J. 2006. Molecular epidemiology of  
416 methicillin-resistant coagulase-negative staphylococci in a Swedish county hospital: evidence  
417 of intra- and interhospital clonal spread. *J Hosp Infect* 64:177-83.
- 418 14. Widerstrom M, McCullough CA, Coombs GW, Monsen T, Christiansen KJ. 2012. A  
419 multidrug-resistant *Staphylococcus epidermidis* clone (ST2) is an ongoing cause of hospital-  
420 acquired infection in a Western Australian hospital. *J Clin Microbiol* 50:2147-51.
- 421 15. Mendes RE, Deshpande LM, Costello AJ, Farrell DJ. 2012. Molecular epidemiology of  
422 *Staphylococcus epidermidis* clinical isolates from U.S. hospitals. *Antimicrob Agents*  
423 *Chemother* 56:4656-61.
- 424 16. Miragaia M, Couto I, Pereira SF, Kristinsson KG, Westh H, Jarlov JO, Carrico J, Almeida J,  
425 Santos-Sanches I, de Lencastre H. 2002. Molecular characterization of methicillin-resistant  
426 *Staphylococcus epidermidis* clones: evidence of geographic dissemination. *J Clin Microbiol*  
427 40:430-8.
- 428 17. Conlan S, Mijares LA, Program NCS, Becker J, Blakesley RW, Bouffard GG, Brooks S,  
429 Coleman H, Gupta J, Gurson N, Park M, Schmidt B, Thomas PJ, Otto M, Kong HH, Murray  
430 PR, Segre JA. 2012. *Staphylococcus epidermidis* pan-genome sequence analysis reveals  
431 diversity of skin commensal and hospital infection-associated isolates. *Genome Biol*  
432 13:R64.

- 433 18. Widerstrom M, Wistrom J, Ek E, Edebro H, Monsen T. 2011. Near absence of methicillin-  
434 resistance and pronounced genetic diversity among *Staphylococcus epidermidis* isolated  
435 from healthy persons in northern Sweden. *APMIS* 119:505-12.
- 436 19. Widerstrom M, Wistrom J, Edebro H, Marklund E, Backman M, Lindqvist P, Monsen T.  
437 2016. Colonization of patients, healthcare workers, and the environment with healthcare-  
438 associated *Staphylococcus epidermidis* genotypes in an intensive care unit: a prospective  
439 observational cohort study. *BMC Infect Dis* 16:743.
- 440 20. Lee JYH, Monk IR, Goncalves da Silva A, Seemann T, Chua KYL, Kearns A, Hill R,  
441 Woodford N, Bartels MD, Strommenger B, Laurent F, Dodemont M, Deplano A, Patel R,  
442 Larsen AR, Korman TM, Stinear TP, Howden BP. 2018. Global spread of three multidrug-  
443 resistant lineages of *Staphylococcus epidermidis*. *Nat Microbiol* 3:1175-1185.
- 444 21. Li X, Arias CA, Aitken SL, Galloway Pena J, Panesso D, Chang M, Diaz L, Rios R, Numan  
445 Y, Ghaoui S, DebRoy S, Bhatti MM, Simmons DE, Raad I, Hachem R, Folan SA,  
446 Sahasarabhojane P, Kalia A, Shelburne SA. 2018. Clonal Emergence of Invasive Multidrug-  
447 Resistant *Staphylococcus epidermidis* Deconvoluted via a Combination of Whole-Genome  
448 Sequencing and Microbiome Analyses. *Clin Infect Dis* 67:398-406.
- 449 22. Both A, Huang J, Qi M, Lausmann C, Weisselberg S, Buttner H, Lezius S, Failla AV,  
450 Christner M, Stegger M, Gehrke T, Baig S, Citak M, Alawi M, Aepfelbacher M, Rohde H.  
451 2021. Distinct clonal lineages and within-host diversification shape invasive *Staphylococcus*  
452 *epidermidis* populations. *PLoS Pathog* 17:e1009304.
- 453 23. Mansson E, Bech Johannesen T, Nilsson-Augustinsson A, Soderquist B, Stegger M. 2021.  
454 Comparative genomics of *Staphylococcus epidermidis* from prosthetic-joint infections and  
455 nares highlights genetic traits associated with antimicrobial resistance, not virulence. *Microb*  
456 *Genom* doi:10.1099/mgen.0.000504.
- 457 24. Hellmark B, Soderquist B, Unemo M, Nilsson-Augustinsson A. 2013. Comparison of  
458 *Staphylococcus epidermidis* isolated from prosthetic joint infections and commensal isolates

- 459 in regard to antibiotic susceptibility, agr type, biofilm production, and epidemiology. *Int J*  
460 *Med Microbiol* 303:32-9.
- 461 25. Harris LG, Bodger O, Post V, Mack D, Morgenstern M, Rohde H, Moriarty TF, Wilkinson  
462 TS. 2020. Temporal Changes in Patient-Matched *Staphylococcus epidermidis* Isolates from  
463 Infections: towards Defining a 'True' Persistent Infection. *Microorganisms* 8.
- 464 26. ECDC. Rapid risk assessment: Multidrug-resistant *Staphylococcus epidermidis* – 8  
465 November 2018.
- 466 27. Widerstrom M. 2016. Significance of *Staphylococcus epidermidis* in Health Care-  
467 Associated Infections, from Contaminant to Clinically Relevant Pathogen: This Is a Wake-  
468 Up Call! *J Clin Microbiol* 54:1679-1681.
- 469 28. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N,  
470 Hanssen A, Wilson WR, Infectious Diseases Society of A. 2013. Diagnosis and  
471 management of prosthetic joint infection: clinical practice guidelines by the Infectious  
472 Diseases Society of America. *Clin Infect Dis* 56:e1-e25.
- 473 29. Parvizi J, Zmistowski B, Berbari EF, Bauer TW, Springer BD, Della Valle CJ, Garvin KL,  
474 Mont MA, Wongworawat MD, Zalavras CG. 2011. New definition for periprosthetic joint  
475 infection: from the Workgroup of the Musculoskeletal Infection Society. *Clin Orthop Relat*  
476 *Res* 469:2992-4.
- 477 30. Amanatullah D, Dennis D, Oltra EG, Marcelino Gomes LS, Goodman SB, Hamlin B,  
478 Hansen E, Hashemi-Nejad A, Holst DC, Komnos G, Koutalos A, Malizos K, Martinez  
479 Pastor JC, McPherson E, Meermans G, Mooney JA, Mortazavi J, Parsa A, Pecora JR,  
480 Pereira GA, Martos MS, Shohat N, Shope AJ, Zullo SS. 2019. Hip and Knee Section,  
481 Diagnosis, Definitions: Proceedings of International Consensus on Orthopedic Infections. *J*  
482 *Arthroplasty* 34:S329-S337.
- 483 31. Harris LG, Murray S, Pascoe B, Bray J, Meric G, Magerios L, Wilkinson TS, Jeeves R,  
484 Rohde H, Schwarz S, de Lencastre H, Miragaia M, Rolo J, Bowden R, Jolley KA, Maiden

- 485 MC, Mack D, Sheppard SK. 2016. Biofilm Morphotypes and Population Structure among  
486 *Staphylococcus epidermidis* from Commensal and Clinical Samples. PLoS One  
487 11:e0151240.
- 488 32. Bogut A, Niedzwiadek J, Koziol-Montewka M, Strzelec-Nowak D, Blacha J, Mazurkiewicz  
489 T, Marczyński W, Plewik D. 2014. Characterization of *Staphylococcus epidermidis* and  
490 *Staphylococcus warneri* small-colony variants associated with prosthetic-joint infections. J  
491 Med Microbiol 63:176-85.
- 492 33. Maduka-Ezeh AN, Greenwood-Quaintance KE, Karau MJ, Barbari EF, Osmon DR,  
493 Hanssen AD, Steckelberg JM, Patel R. 2012. Antimicrobial susceptibility and biofilm  
494 formation of *Staphylococcus epidermidis* small colony variants associated with prosthetic  
495 joint infection. Diagn Microbiol Infect Dis 74:224-9.
- 496 34. Tevell S, Baig S, Nilsson-Augustinsson A, Stegger M, Soderquist B. 2019. Same  
497 Organism, Different Phenotype - Are Phenotypic Criteria Adequate In Coagulase-Negative  
498 Staphylococcal Orthopaedic Implant-Associated Infections? J Bone Jt Infect 4:16-19.
- 499 35. Kärrholm M. Annual Report 2016. The Swedish Hip Arthroplasty Register  
500 <https://shpr.registercentrum.se>
- 501 36. Sundberg M. Annual Report 2016. The Swedish Knee Arthroplasty Register.  
502 [https://www.myknee.se/pdf/SVK\\_2016\\_Eng\\_1.0.pdf](https://www.myknee.se/pdf/SVK_2016_Eng_1.0.pdf)
- 503 37. Harris LG, El-Bouri K, Johnston S, Rees E, Frommelt L, Siemssen N, Christner M, Davies  
504 AP, Rohde H, Mack D. 2010. Rapid identification of staphylococci from prosthetic joint  
505 infections using MALDI-TOF mass-spectrometry. Int J Artif Organs 33:568-74.
- 506 38. Widerstrom M, Monsen T, Karlsson C, Edebro H, Johansson A, Wistrom J. 2009. Clonality  
507 among multidrug-resistant hospital-associated *Staphylococcus epidermidis* in northern  
508 Europe. Scand J Infect Dis 41:642-9.
- 509 39. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM,  
510 Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G,

- 511 Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its  
512 applications to single-cell sequencing. *J Comput Biol* 19:455-77.
- 513 40. Sahl JW, Lemmer D, Travis J, Schupp JM, Gillece JD, Aziz M, Driebe EM, Drees KP,  
514 Hicks ND, Williamson CHD, Hepp CM, Smith DE, Roe C, Engelthaler DM, Wagner DM,  
515 Keim P. 2016. NASP: an accurate, rapid method for the identification of SNPs in WGS  
516 datasets that supports flexible input and output formats. *Microb Genom* 2:e000074.
- 517 41. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, Garimella K,  
518 Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a  
519 MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*  
520 20:1297-303.
- 521 42. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New  
522 algorithms and methods to estimate maximum-likelihood phylogenies: assessing the  
523 performance of PhyML 3.0. *Syst Biol* 59:307-21.
- 524 43. Lefort V, Longueville JE, Gascuel O. 2017. SMS: Smart Model Selection in PhyML. *Mol*  
525 *Biol Evol* 34:2422-2424.
- 526 44. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM,  
527 Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. *J Antimicrob*  
528 *Chemother* 67:2640-4.
- 529 45. Galdbart JO, Morvan A, Desplaces N, el Solh N. 1999. Phenotypic and genomic variation  
530 among *Staphylococcus epidermidis* strains infecting joint prostheses. *J Clin Microbiol*  
531 37:1306-12.
- 532 46. Van Eldere J, Peetermans WE, Struelens M, Deplano A, Bobbaers H. 2000. Polyclonal  
533 *Staphylococcal* endocarditis caused by genetic variability. *Clin Infect Dis* 31:24-30.
- 534 47. Dengler Haunreiter V, Boumassoud M, Haffner N, Wipfli D, Leimer N, Rachmuhl C,  
535 Kuhnert D, Achermann Y, Zbinden R, Benussi S, Vulin C, Zinkernagel AS. 2019. In-host

- 536 evolution of *Staphylococcus epidermidis* in a pacemaker-associated endocarditis resulting in  
537 increased antibiotic tolerance. *Nat Commun* 10:1149.
- 538 48. Dudareva M, Barrett L, Figtree M, Scarborough M, Watanabe M, Newnham R, Wallis R,  
539 Oakley S, Kendrick B, Stubbs D, McNally MA, Bejon P, Atkins BA, Taylor A, Brent AJ.  
540 2018. Sonication versus Tissue Sampling for Diagnosis of Prosthetic Joint and Other  
541 Orthopedic Device-Related Infections. *J Clin Microbiol* 56.
- 542 49. Kourbatova EV, Halvosa JS, King MD, Ray SM, White N, Blumberg HM. 2005.  
543 Emergence of community-associated methicillin-resistant *Staphylococcus aureus* USA 300  
544 clone as a cause of health care-associated infections among patients with prosthetic joint  
545 infections. *Am J Infect Control* 33:385-91.
- 546 50. Luedicke C, Slickers P, Ehricht R, Monecke S. 2010. Molecular fingerprinting of  
547 *Staphylococcus aureus* from bone and joint infections. *Eur J Clin Microbiol Infect Dis*  
548 29:457-63.
- 549 51. Wildeman P, Tevell S, Eriksson C, Lagos AC, Soderquist B, Stenmark B. 2020. Genomic  
550 characterization and outcome of prosthetic joint infections caused by *Staphylococcus*  
551 *aureus*. *Sci Rep* 10:5938.
- 552 52. Meric G, Mageiros L, Pensar J, Laabei M, Yahara K, Pascoe B, Kittiwon N, Tadee P, Post  
553 V, Lamble S, Bowden R, Bray JE, Morgenstern M, Jolley KA, Maiden MCJ, Feil EJ,  
554 Didelot X, Miragaia M, de Lencastre H, Moriarty TF, Rohde H, Massey R, Mack D,  
555 Corander J, Sheppard SK. 2018. Disease-associated genotypes of the commensal skin  
556 bacterium *Staphylococcus epidermidis*. *Nat Commun* 9:5034.
- 557 53. Saffari F, Widerstrom M, Gurram BK, Edebro H, Hojabri Z, Monsen T. 2016. Molecular  
558 and Phenotypic Characterization of Multidrug-Resistant Clones of *Staphylococcus*  
559 *epidermidis* in Iranian Hospitals: Clonal Relatedness to Healthcare-Associated Methicillin-  
560 Resistant Isolates in Northern Europe. *Microb Drug Resist* 22:570-577.

- 561 54. Post V, Harris LG, Morgenstern M, Mageiros L, Hitchings MD, Meric G, Pascoe B,  
562 Sheppard SK, Richards RG, Moriarty TF. 2017. Comparative Genomics Study of  
563 *Staphylococcus epidermidis* Isolates from Orthopedic-Device-Related Infections Correlated  
564 with Patient Outcome. *J Clin Microbiol* 55:3089-3103.
- 565 55. Flurin L, Greenwood-Quaintance KE, Patel R. 2019. Microbiology of polymicrobial  
566 prosthetic joint infection. *Diagn Microbiol Infect Dis* 94:255-259.
- 567 56. Proctor RA. 2000. Editorial response: coagulase-negative staphylococcal infections: A  
568 diagnostic and therapeutic challenge. *Clin Infect Dis* 31:31-3.
- 569 57. Rendboe AK, Johannesen TB, Ingham AC, Mansson E, Iversen S, Baig S, Edslev S, Jensen  
570 JS, Soderquist B, Andersen PS, Stegger M. 2020. The Epidome - a species-specific  
571 approach to assess the population structure and heterogeneity of *Staphylococcus epidermidis*  
572 colonization and infection. *BMC Microbiol* 20:362.
- 573 58. Taxt AM, Avershina E, Frye SA, Naseer U, Ahmad R. 2020. Rapid identification of  
574 pathogens, antibiotic resistance genes and plasmids in blood cultures by nanopore  
575 sequencing. *Sci Rep* 10:7622.
- 576



577 **Figure legends**

578 **Fig 1:** Midpoint-rooted maximum-likelihood phylogeny of 69 *S. epidermidis* PJI isolates from 16  
579 patients. Information on sequence type, genes related to resistance, virulence and biofilm formation  
580 is presented as is the patient number. Scale bar indicate substitutions per site. Black blocks  
581 represent presence of genes mediating antibiotic resistance or genes previously associated with  
582 virulence.

583 **Fig 2.** Pairwise SNP within-patient and between-patients SNP distances among *S. epidermidis*  
584 isolates belonging to ST2/ST188, ST59/ST965 and ST215/ST434 PJI patients. \*\*\*\* =  $p < 0.0001$ ,  
585 \*\* = 0.002

586 **Fig 3.** Pairwise within-patient SNP distances among 16 PJI patients where  $\geq 2$  *S. epidermidis* isolate  
587 were available for analysis. Different colors depict different STs

588 **Fig S1.** Flowchart depicting the 62 CoNS PJI patients included in the study and the 16 *S.*  
589 *epidermidis* prosthetic joint infections with multiple isolates analyzed by WGS

590 **Fig. S2.** Dendrogram cluster analysis of the genetic similarity of 131 CoNS isolates using pulsed-  
591 field gel electrophoresis (PFGE). The horizontal upper bar indicates genetic similarity (per cent).  
592 The dotted lines in the centre of the diagram represent digitalized transformation of the PFGE DNA  
593 pattern. The columns to the right present the following: patient ID, PFGE type or non-*S.*  
594 *epidermidis* species and sequence type (ST).

595 **Fig S3.** Intra-lineage pairwise SNP diversity among *S. epidermidis* STs within each patient with PJI  
596 related to time since primary surgery

597

**Table 1.** Demographics and clinical characteristics of 62 consecutive patients with prosthetic joint infections due to coagulase-negative staphylococci

| Characteristics                                          | Total (%)           |
|----------------------------------------------------------|---------------------|
| Median age (IQR), yr                                     | 68.6<br>(60.5-77.5) |
| No. of female patients                                   | 28 (45)             |
| Arthroplasty                                             |                     |
| Hip                                                      | 38 (61)             |
| Knee                                                     | 21 (34)             |
| Other: elbow ( <i>n</i> =1), shoulder ( <i>n</i> =2)     | 3 (5)               |
| Reason for primary arthroplasty                          |                     |
| Osteoarthritis                                           | 36 (60)             |
| Fracture or trauma                                       | 15 (32)             |
| Rheumatoid arthritis                                     | 11 (8)              |
| IDSA PJI criteria                                        |                     |
| Identical organism identified with two separate cultures | 62 (100)            |
| Presence of sinus tract                                  | 9 (15)              |
| Visible purulence at implant site                        | 52 (84)             |
| Surgical procedure                                       | 62 (100)            |
| Debridement and implant retention                        | 21 (34)             |
| Revision (one-stage exchange)                            | 6 (10)              |
| Resection (two-stage exchange or resection)              | 35 (56)             |
| Type of revision                                         |                     |
| Primary                                                  | 35 (56)             |
| Secondary                                                | 27 (44)             |
| Timing from prosthesis implanted to surgery (mo)         |                     |
| Early onset (<3)                                         | 37 (60)             |
| Delayed onset (3 to 12)                                  | 11 (18)             |
| Late onset (>12)                                         | 14 (22)             |
| Hospitalized previous year                               |                     |
| Yes                                                      | 36 (58)             |
| No                                                       | 26 (42)             |
| Failure 2-year follow-up                                 |                     |
| Yes                                                      | 15 (24)             |
| No                                                       | 46 (74)             |

Abbreviation list: mo = month, IDSA= Infectious Disease Society of America

**Table 2.** Microbiological characteristics in 62 consecutive patients with prosthetic joint infections due to coagulase-negative staphylococci

| Microbiology                    | Monomicrobial<br><i>n</i> = 43 (69%)<br><i>n</i> | Polymicrobial<br><i>n</i> = 19 (31%)<br><i>n</i> | Total<br><i>n</i> = 62<br><i>n</i> |
|---------------------------------|--------------------------------------------------|--------------------------------------------------|------------------------------------|
| <i>S. epidermidis</i>           | 33                                               | 19                                               | 52                                 |
| <i>S. capitis</i>               | 5                                                | 0                                                | 5                                  |
| <i>S. hominis</i>               | 2                                                | 3                                                | 5                                  |
| <i>S. lugdunensis</i>           | 1                                                | 1                                                | 2                                  |
| <i>S. caprae</i>                | 1                                                | 0                                                | 1                                  |
| <i>S. warneri</i>               | 1                                                | 0                                                | 1                                  |
| <i>S. haemolyticus</i>          |                                                  | 1                                                | 1                                  |
| <i>E. faecalis</i> <sup>a</sup> |                                                  | 7                                                | 7                                  |
| <i>E. coli</i> <sup>b</sup>     |                                                  | 3                                                | 3                                  |
| <i>S. aureus</i> <sup>b</sup>   |                                                  | 2                                                | 2                                  |
| <i>S. dysgalactiae</i> (GGS)    |                                                  | 1                                                | 1                                  |
| <i>C. acnes</i>                 |                                                  | 1                                                | 1                                  |
| <i>Peptostreptococcus</i>       |                                                  | 1                                                | 1                                  |
| <i>Enterobacter</i>             |                                                  | 1                                                | 1                                  |

<sup>a</sup>Two cases including *E. coli* and *S. aureus*, respectively

<sup>b</sup>One case including *E. faecalis*

**Table 3.** Within-patient polymorphism in phenotypic antimicrobial susceptibility pattern among 16prosthetic joint infections with  $\geq 2$  isolates of *S. epidermidis*


| Patient ID | ST  | Isolates<br>(n) | FUS | FOX | GEN | CLI | ERY | NOR | RIF | SXT |
|------------|-----|-----------------|-----|-----|-----|-----|-----|-----|-----|-----|
| <b>1</b>   | 59  | 1               | R   | S   | S   | S   | S   | S   | S   | S   |
|            | 215 | 2               | R   | S   | R   | R   | R   | R   | S   | R   |
|            | 215 | 1               | R   | R   | R   | S   | S   | R   | S   | R   |
|            | 215 | 2               | R   | S   | R   | S   | S   | R   | S   | R   |
|            | 215 | 2               | R   | R   | R   | R   | R   | R   | S   | R   |
| <b>2</b>   | 2   | 9               | S   | R   | R   | R   | R   | R   | R   | R   |
| <b>12</b>  | 2   | 2               | S   | R   | R   | R   | R   | R   | R   | R   |
|            | 73  | 1               | S   | S   | S   | S   | S   | S   | S   | S   |
| <b>28</b>  | 2   | 1               | S   | R   | S   | R   | R   | R   | S   | R   |
|            | 2   | 1               | R   | R   | R   | R   | R   | R   | S   | R   |
| <b>37</b>  | 2   | 1               | S   | S   | R   | R   | R   | R   | R   | R   |
|            | 2   | 2               | S   | R   | R   | S   | S   | R   | R   | R   |
|            | 152 | 1               | S   | S   | S   | S   | S   | S   | S   | S   |
|            | 215 | 1               | R   | R   | R   | R   | R   | R   | S   | R   |
|            | 961 | 1               | S   | S   | S   | S   | S   | S   | S   | S   |
| <b>40</b>  | 215 | 3               | R   | R   | R   | S   | S   | R   | S   | R   |
|            | 215 | 1               | R   | S   | R   | R   | R   | R   | S   | R   |
| <b>42</b>  | 188 | 3               | R   | R   | R   | R   | R   | R   | S   | R   |
|            | 188 | 1               | R   | R   | R   | S   | S   | R   | S   | R   |
| <b>43</b>  | 2   | 4               | S   | R   | R   | R   | R   | R   | S   | R   |
|            | 2   | 1               | S   | R   | R   | S   | S   | R   | S   | R   |
| <b>46</b>  | 89  | 2               | S   | S   | R   | S   | S   | S   | S   |     |
| <b>47</b>  | 2   | 2               | S   | R   | R   | R   | R   | R   | S   | R   |
| <b>49</b>  | 965 | 5               | S   | R   | R   | S   | S   | S   | S   | S   |
|            | 965 | 1               | R   | R   | R   | S   | R   | S   | S   | S   |
|            | 965 | 1               | S   | R   | R   | S   | R   | S   | S   | S   |
| <b>50</b>  | 215 | 1               | R   | R   | R   | R   | R   | R   | S   | R   |
|            | 434 | 1               | R   | R   | R   | R   | R   | R   | R   | R   |
| <b>54</b>  | 225 | 1               | S   | S   | S   | S   | S   | S   | S   | S   |
|            | 434 | 3               | R   | R   | R   | R   | R   | R   | R   | R   |
|            | 723 | 1               | S   | S   | R   | S   | S   | S   | S   | S   |
|            | 962 | 1               | S   | S   | S   | S   | S   | S   | S   | S   |
|            | 964 | 1               | S   | S   | S   | S   | S   | S   | S   | S   |
| <b>56</b>  | 2   | 2               | S   | R   | R   | S   | S   | R   | R   | R   |
|            | 2   | 1               | S   | R   | R   | R   | R   | R   | R   | R   |
| <b>58</b>  | 2   | 1               | S   | R   | R   | R   | R   | R   | S   | R   |
|            | 2   | 1               | S   | R   | R   | R   | R   | R   | R   | R   |
|            | 188 | 1               | R   | R   | R   | R   | R   | R   | R   | R   |
| <b>60</b>  | 5   | 1               | S   | S   | R   | S   | R   | S   | S   | S   |
|            | 86  | 1               | S   | S   | R   | S   | S   | S   | R   | S   |

**Table 4:** Within-patient phenotypic and genotypic polymorphism among 16 patients with *S. epidermidis* PJI where  $\geq 2$  isolate were analyzed using WGS


| Patient ID | Type of implant | Classification <sup>a</sup> | No. of specimens included | No. of <i>S. epidermidis</i> isolates | No. of different antibiograms | ST                         | Polymicrobial | Additional species                    |
|------------|-----------------|-----------------------------|---------------------------|---------------------------------------|-------------------------------|----------------------------|---------------|---------------------------------------|
| 2          | Hip             | Early                       | 7                         | 9                                     | 1                             | 2                          | No            |                                       |
| 12         | Hip             | Early                       | 3                         | 3                                     | 2                             | 2, 73                      | Yes           | <i>S. hominis</i>                     |
| 28         | Hip             | Early                       | 2                         | 2                                     | 2                             | 2                          | No            |                                       |
| 46         | Hip             | Early                       | 2                         | 2                                     | 1                             | 89                         | No            |                                       |
| 47         | Hip             | Delayed                     | 2                         | 2                                     | 1                             | 2                          | Yes           | <i>E. faecalis:</i><br><i>E. coli</i> |
| 50         | Hip             | Delayed                     | 2                         | 2                                     | 2                             | 215, 434                   | Yes           | <i>E. faecalis</i>                    |
| 56         | Hip             | Delayed                     | 2                         | 3                                     | 2                             | 2                          | No            |                                       |
| 1          | Hip             | Late                        | 4                         | 8                                     | 5                             | 59, 215                    | Yes           | <i>S. hominis</i>                     |
| 40         | Hip             | Late                        | 4                         | 4                                     | 2                             | 215                        | Yes           | <i>S. haemolyticus</i>                |
| 43         | Knee            | Early                       | 5                         | 5                                     | 2                             | 2                          | No            |                                       |
| 54         | Knee            | Early                       | 6                         | 7                                     | 3                             | 225, 434, 723,<br>962, 964 | Yes           | <i>S. hominis</i>                     |
| 58         | Knee            | Early                       | 3                         | 3                                     | 3                             | 2, 188                     | No            |                                       |
| 60         | Knee            | Early                       | 2                         | 2                                     | 2                             | 5, 86                      | Yes           | <i>S. lugdunensis</i>                 |
| 42         | Knee            | Delayed                     | 4                         | 4                                     | 2                             | 188                        | No            |                                       |
| 49         | Knee            | Late                        | 7                         | 7                                     | 3                             | 965                        | No            |                                       |
| 37         | Shoulder        | Late                        | 5                         | 6                                     | 4                             | 2, 152, 215,<br>961        | No            |                                       |

<sup>a</sup>Early = <3 months, Delayed = 3-12 months, Late = >12 months

**Fig 1:** Midpoint-rooted maximum-likelihood phylogeny of 69 *S. epidermidis* PJI isolates from 16 patients. Information on sequence type, genes related to resistance, virulence and biofilm formation is presented as is the patient number. Scale bar indicate substitutions per site. Black blocks represent presence of genes mediating antibiotic resistance or genes previously associated with virulence.



**Fig 2.** Pairwise SNP within-patient and between-patients SNP distances among *S. epidermidis* isolates belonging to ST2/ST188, ST59/ST965 and ST215/ST434 PJI patients. \*\*\*\* =  $p < 0.0001$ , \*\* = 0.002



**Fig 3.** Pairwise within-patient SNP distances among 16 PJI patients where  $\geq 2$  *S. epidermidis* isolate were available for analysis. Different colors depict different STs

